Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Zolmitriptan
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Emergex Vaccines Holding
Deal Size : Undisclosed
Deal Type : Acquisition
Details : The assets acquired include Zosano’s proprietary microneedle array patch (MAP) intradermal drug delivery system, intended for the epidermal delivery of M207 (zolmitriptan) for the treatment of migraine attacks in adults.
Brand Name : M207
Molecule Type : Small molecule
Upfront Cash : Undisclosed
December 18, 2023
Lead Product(s) : Zolmitriptan
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Emergex Vaccines Holding
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : CD8+ T-cell Adaptive Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Emergex Vaccines Holding
Deal Size : Undisclosed
Deal Type : Acquisition
Details : The MAP technology developed by Zosano is an exceptional strategic fit that complements our CD8+ T cell Adaptive Vaccine platform and intend to develop the MAP technology acquired from Zosano for delivery of vaccines.
Brand Name : Undisclosed
Molecule Type : Vaccine
Upfront Cash : Undisclosed
October 12, 2022
Lead Product(s) : CD8+ T-cell Adaptive Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Emergex Vaccines Holding
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Zolmitriptan
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Company has received feedback from the U.S. Food and Drug Administration Division of Neurology II (the “Division”) on the protocol for the pharmacokinetic study required to support the resubmission of the Qtrypta™ NDA.
Brand Name : Qtrypta
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 26, 2021
Lead Product(s) : Zolmitriptan
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Zolmitriptan
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Zosano Pharma Confirms NDA Resubmission Strategy Following Type A Meeting Minutes from FDA
Details : Company has received the official Type A meeting minutes from the U.S. FDA Division of Neurology II regarding the requirements for resubmission of the Qtrypta™ New Drug Application following the Complete Response Letter received on October 20, 2020.
Brand Name : Qtrypta
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 22, 2021
Lead Product(s) : Zolmitriptan
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Zolmitriptan
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Zosano Pharma Receives Complete Response Letter from FDA for Qtrypta™
Details : The CRL cited inconsistent zolmitriptan exposure levels observed across clinical pharmacology studies and recommended the company to conduct a repeat bioequivalence study between three of the lots used during development.
Brand Name : Qtrypta
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 21, 2020
Lead Product(s) : Zolmitriptan
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Zolmitriptan
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Zosano Pharma Receives Preliminary FDA Communication on Qtrypta™ NDA
Details : The DRL described two concerns regarding clinical pharmacology section of the NDA; (i) regarding unexpected high plasma concentrations of zolmitriptan observed from two pharmacokinetic studies; (ii) the FDA raised questions regarding differences in zolmi...
Brand Name : Qtrypta
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 30, 2020
Lead Product(s) : Zolmitriptan
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Zolmitriptan
Therapeutic Area : Neurology
Study Phase : Phase III
Recipient : Eversana
Deal Size : Undisclosed
Deal Type : Partnership
Details : Zosano and EVERSANA will utilize EVERSANA’s commercial execution expertise for marketing, market access, distribution, sales force deployment, reimbursement, and patient adherence support services. EVERSANA to commercialize and distribute Qtrypta™ in...
Brand Name : Qtrypta
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 06, 2020
Lead Product(s) : Zolmitriptan
Therapeutic Area : Neurology
Highest Development Status : Phase III
Recipient : Eversana
Deal Size : Undisclosed
Deal Type : Partnership
LOOKING FOR A SUPPLIER?